Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics
Horizon Discovery, a company specializing in the application of gene editing and gene modulation for cell line engineering, has announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognized in the industry and by regulators as suitable for high yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production. CHOSOURCE has been utilized in multiple successful Innovative New Drug (IND) filings.
Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.”